NYSE:LLY 20 February 2026

Novo Nordisk Stock Jumps After Wegovy Pill Sales Surprise in Lilly Obesity Fight

Novo Nordisk bumped up its 2026 forecast on Wednesday, buoyed by stronger-than-expected initial sales for its Wegovy weight-loss pill—a fresh win in its rivalry with Eli Lilly. In Copenhagen, the stock jumped up to 9.2% after Novo told investors it now expects this year’s drops in sales and profit to be less steep than it previously warned.

6 May 2026

NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Cabaletta Bio Stock Jumps: Inside the $150 Million Bet on CABA’s Cell Therapy

Shares of Cabaletta Bio Inc. surged roughly 32% late Monday, buoyed by news of early results from a small cell-therapy trial and the announcement of a $150 million stock sale that counted Eli Lilly among its participants. Trading hit $3.895 on strong volume, topping out intraday at $4.04, according to market data.

4 May 2026

Biotechnology·Healthcare Innovation·NASDAQ:CABA·NYSE:LLY·Stock Market

Eli Lilly Raises 2026 Forecast as Mounjaro, Zepbound Sales Keep Weight-Loss Boom Alive

Eli Lilly hiked its full-year outlook for both sales and profit Thursday, following a jump in quarterly revenue driven by strong uptake of its diabetes drug Mounjaro and obesity therapy Zepbound. First-quarter revenue climbed 56% to $19.8 billion, according to the Indianapolis-based company, with adjusted earnings coming in at $8.55 per share.

30 April 2026

Financial Forecasts·NYSE:LLY·Pharmaceuticals

Eli Lilly’s New Weight-Loss Pill Has an Early Problem: Novo’s Head Start

Prescriptions for Eli Lilly and Company’s new oral weight-loss drug Foundayo reached 3,707 in the U.S. during its second week, according to IQVIA data cited by analysts. That’s behind the early numbers seen for Novo Nordisk’s competing Wegovy pill and has weighed on Lilly shares. In its launch week, Foundayo saw 1,390 prescriptions.

24 April 2026

Health News·NYSE:LLY·NYSE:NVO·Pharmaceuticals

Novo Nordisk Stock Gets Wegovy Pill Boost as Eli Lilly’s Foundayo Starts Slow

Novo Nordisk A/S’s Wegovy pill stayed ahead in the early going, with 18,410 U.S. prescriptions at the same stage of launch where Eli Lilly’s Foundayo managed 3,707 in its second week, according to analysts referencing IQVIA data. RBC Capital Markets analyst Trung Huynh flagged that it’s early days and comparisons can be tricky, but noted that Foundayo’s latest numbers are likely to be viewed as a disappointment.

24 April 2026

NYSE:LLY·NYSE:NVO·Pharmaceuticals

Hims Adds Lilly’s Zepbound and Foundayo as GLP-1 Price Fight Moves Online

Hims & Hers Health announced Thursday that its providers are now able to send prescriptions for Eli Lilly’s Zepbound vials, the Zepbound KwikPen, and the Foundayo pill directly to LillyDirect. With this move, the telehealth company is expanding its reach into branded obesity treatments. The company said that, combined with its previous Novo Nordisk partnership, it now offers what it describes as the full lineup of FDA-approved GLP-1 drugs on its platform.

23 April 2026

NYSE:HIMS·NYSE:LLY·NYSE:NVO·Pharmaceuticals

Hims & Hers Stock Slides as Amazon Enters the GLP-1 Weight-Loss Race

Hims & Hers Health dropped 1.6% to $30.52 in afternoon trading Tuesday, sliding after Amazon rolled out a GLP-1 weight-management program via One Medical. Shares, which opened at $28.31 and touched a session low of $28.01, took a hit as the telehealth firm faces increased heat to revamp its weight-loss segment.

21 April 2026

NASDAQ:AMZN·NASDAQ:HIMS·NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Eli Lilly to Buy Kelonia for Up to $7 Billion as In Vivo CAR-T Gains Ground

Eli Lilly on Monday agreed to buy Boston’s Kelonia Therapeutics in a deal valued at up to $7 billion in cash, adding a fresh in vivo cell therapy play to its pipeline. The drugmaker will pay $3.25 billion upfront, with the balance subject to hitting clinical, regulatory, and commercial milestones.

21 April 2026

Biotechnology·NYSE:LLY·Pharmaceuticals

Eli Lilly to Buy Kelonia for Up to $7 Billion in Bet on Next-Gen CAR-T Cancer Therapy

Eli Lilly agreed to acquire Boston-based Kelonia Therapeutics for up to $7 billion on Monday, handing the drugmaker a new bet on experimental cell therapies for blood cancer as it keeps widening its pipeline beyond weight-loss medicines. Lilly shares were up about 2.5% in morning trading.

20 April 2026

Healthcare Innovation·NYSE:LLY

Eli Lilly and Company Stock Price: LLY Closes at $878.24 as Insilico Deal, Trial Data Put Monday in Focus

Eli Lilly kicks off the week with a fresh pipeline pact in hand. Insilico Medicine on Sunday announced it struck a global licensing and research deal with the U.S. pharma giant, a tie-up valued at as much as $2.75 billion. Lilly shares finished Friday at $878.24, off 2.1%. The stock sits more than 22% beneath its Jan. 8 peak.

29 March 2026

NYSE:LLY·Pharmaceuticals·Stock Market

Eli Lilly Stock Wobbles After Retatrutide Trial Win as Pricing Fears Bite

Eli Lilly shares grabbed attention Thursday, with the drugmaker reporting its experimental obesity and diabetes therapy, retatrutide, hit the primary endpoint in a late-stage trial—showing notable drops in both weight and blood sugar. The stock last changed hands at $918.05, off 1.3% early, after Tuesday’s nearly 6% tumble that followed a rare downgrade from HSBC.

19 March 2026

Health News·NYSE:LLY·Pharmaceuticals·Stock Market

Hims & Hers Health Stock Price Jumps Again as Novo Nordisk Truce Sparks Wall Street Upgrades

Hims & Hers Health shares climbed 5.1% to $27.19 in premarket action as of 9:00 a.m. EDT on Thursday, following a 10.3% jump to $25.88 at Wednesday’s close. That put the telehealth company on track for its fourth consecutive advance.

12 March 2026

NASDAQ:HIMS·NYSE:LLY·NYSE:NVO·Stock Market

AbbVie Obesity Drug ABBV-295 Hits Up to 9.8% Weight Loss in Early Trial

AbbVie said on Monday its experimental obesity drug ABBV-295 helped adults lose up to 9.79% of their body weight in 12 weeks in an early-stage study, giving the drugmaker its clearest sign yet that it may have a contender in a market led by Eli Lilly and Novo Nordisk. The company said no serious adverse events were reported.

10 March 2026

Health News·NYSE:ABBV·NYSE:LLY·NYSE:NVO·Pharmaceuticals

Eli Lilly stock slips again as April orforglipron decision and FDA GLP-1 ad crackdown loom

Eli Lilly and Company wrapped up Tuesday’s session down roughly 1%, settling at $1,007.73. That followed a 3.23% drop the previous day.

4 March 2026

NASDAQ:VTYX·NYSE:LLY·Pharmaceuticals·Stock Market

Eli Lilly stock drops 2% as traders eye China approval and a late-day CFO readout

Eli Lilly and Company shares slipped 2.3% to $1,028.07 in Monday afternoon trading. Earlier in the session, the stock climbed as high as $1,056.84 but also dropped to $1,023.50 at its lowest. The drugmaker now holds a market value near $686 billion.

2 March 2026

HKG:1801·NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Eli Lilly stock price rebounds above $1,050 — what traders are watching next

Eli Lilly and Co jumped 2.93% to finish at $1,051.99 on Friday, breaking a three-session slide. U.S. markets remain closed Saturday.

28 February 2026

NYSE:LLY·Stock Market

Eli Lilly stock snaps skid on orforglipron pill data as April FDA clock nears

Shares of Eli Lilly and Company jumped 2.93% to finish at $1,051.99 on Friday, breaking a three-session slump and pulling ahead of a broader market that dropped. The S&P 500 slipped 0.43%, while the Dow lost 1.05%, as traders grappled with stretched valuations and renewed jitters over the speed of artificial intelligence’s impact on market leaders and laggards.

28 February 2026

Biotechnology·NYSE:LLY·Pharmaceuticals·Stock Market

Eli Lilly stock price slips as Zepbound KwikPen FDA nod and Novo trial data keep LLY in focus

Eli Lilly and Company ended Wednesday’s session off 1.28% at $1,028.83, with traders once again zeroing in on the obesity-drug story instead of the wider market action.

26 February 2026

NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod

Eli Lilly jumped roughly 4.9% to $1,058.23 late Monday, after Novo Nordisk revealed its next-gen obesity candidate, CagriSema, didn’t measure up to Lilly’s Zepbound in direct comparison. Novo's U.S. shares dropped sharply, sliding 16.4% to $39.63.

23 February 2026

Biotechnology·NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

CSL share price slips as buyback tally grows; Lilly deal sets up next week

CSL Ltd slipped 0.6% Friday, ending the session at A$153.27. That pullback shaved off some of the gains from a two-day run-up earlier in the week.

20 February 2026

ASX:CSL·NYSE:LLY·Pharmaceutical Industry·Share Buybacks·Stock Market

NYSE:LLY 20 February 2026 - 6 May 2026